The firm is a life sciences-focused investment arm of a broader innovation platform, established recently and based in Europe. The firm is actively deploying capital from an early-stage fund and typically makes initial investments in the low single-digit millions. The firm is open to syndicating with co-investors to support portfolio company growth. While the firm has a current geographic emphasis on regional opportunities, it maintains a global investment outlook.
The firm focuses on early-stage biotechnology opportunities emerging from academic and research environments, with a strong emphasis on translational science progressing toward first-in-human studies. The firm prioritizes therapeutic programs supported by robust preclinical data, including modalities such as peptide-based therapeutics. Areas of interest include indications like chronic and nerve-related conditions, among others. The firm seeks programs with a clear and credible path to clinical entry within a defined development timeline, supported by validated targets, strong in vivo data, and early safety work. While therapeutics is the primary focus, the firm actively collaborates with external partners to advance high-potential biological innovations.
From a company and management team perspective, the firm seeks academic founders and early-stage scientific teams developing differentiated therapeutic candidates with strong translational potential. The firm prioritizes opportunities with defensible intellectual property, rigorous preclinical validation, and well-defined development strategies toward IND-enabling studies. The firm works closely with portfolio companies by providing scientific, regulatory, and operational support and engages with teams capable of executing early development milestones. The firm is open to leading or co-leading rounds and partnering with additional investors to support clinical and commercial advancement.
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.
Next Phase Newsletter 
Leave a comment